Rhizen Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Rhizen Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Rhizen Pharmaceuticals: 7 sponsored US clinical trials, none currently recruiting.

Rhizen Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, T-Cell, Cutaneous, with 1 trials.

Upper-quartile sponsor footprint

Rhizen Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 1

A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects

NCT04680429
COMPLETED Phase 1

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

NCT03770000
COMPLETED Phase 1

Compassionate Use Study of Tenalisib (RP6530)

NCT03711604
COMPLETED Phase 2

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT03711578
TERMINATED Phase 1

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

NCT03471351
TERMINATED Phase 1

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467
COMPLETED Phase 1

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1

Therapeutic Areas

Lymphoma, T-Cell, Cutaneous 1
Lymphoma, T-Cell, Peripheral 1
Hematological Malignancies 1

How the Rhizen Pharmaceuticals early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Lymphoma, T-Cell, Cutaneous (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Rhizen Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Rhizen Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Rhizen Pharmaceuticals3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Rhizen Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rhizen Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rhizen Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of Rhizen Pharmaceuticals or any single study.

  • None of Rhizen Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lymphoma, T-Cell, Cutaneous is the condition Rhizen Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, T-Cell, Cutaneous trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rhizen Pharmaceuticals pipeline card: 7 registered trials from official public datasets.Report a data error.